StockData

Kestra Medical Technologies vs TELA Bio

KMTS and TELA side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How KMTS and TELA compare

Kestra Medical Technologies is the larger company, worth 46 times as much as TELA Bio ($1.7B against $36.8M).

Kestra Medical Technologies grew revenue faster over the last twelve months (60.7% versus 1.5% for TELA Bio).

TELA Bio keeps more of each dollar of sales as profit, with a net margin of −53.6% compared with −140% at Kestra Medical Technologies.

Kestra Medical Technologies scores higher on the StockData Score (5 against 3 for TELA Bio), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricKMTSTELA
Size and price
Market cap$1.7B$36.8M
Share price$28.64$0.820
Change, 1 year6.9%−28.1%
Change, 5 years–−93.5%
Beta (5Y)1.210.62
Employees443218
StockData Score
Total score5 (better)3
Valuation score01 (better)
Growth score3 (better)1
Performance score01 (better)
Health score2 (better)0
Dividend score00
Valuation
P/S16.0×0.5× (better)
FCF yield−7.2% (better)−93.4%
Growth
Revenue growth (TTM)60.7% (better)1.5%
Revenue growth, 5Y average–34.5%
Profitability
Gross margin53.9%67.2% (better)
Operating margin−134%−43.2% (better)
Net margin−140%−53.6% (better)
FCF margin−115%−44.0% (better)
Return on invested capital–−238%
Financial health
Interest coverage−19.0×−4.3× (better)
Current ratio4.69 (better)0.61
Altman Z-score4.94 (better)−13.23
Piotroski F-score4 (better)3
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions98.6%70.5%
Held by insiders44.0%41.0%
Insider net buying, 12 months−$15.3M$186K (better)
Short interest, % of float12.3%2.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.